Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies
Methods and Protocols · 22.12.2025 · 9 (1) · 4
DOI: 10.3390/mps9010004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods and Protocols, online erschienen am 22.12.2025. Verfasst von Gulnur Nakhanova und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Education and Science, scientific and technological programme “Development of new diagnostic test systems for particularly dangerous viral infections”.
Abstract (Originalsprache)
The emergence and spread of coronavirus infections have created a necessity to develop serological methods for assessing population immunity. The enzyme-linked immunosorbent assay (ELISA) remains one of the most accessible and informative approaches for these purposes. The choice of recombinant proteins plays an important role in the sensitivity and specificity of the test system, and in this regard, the creation of a domestic ELISA based on the chimeric SM protein to the SARS-CoV-2 virus is relevant. In this work, a recombinant chimeric SM protein expressed in the E. coli system and purified using metal-affinity chromatography on Ni-NTA agarose was constructed and presented for the first time. An ELISA test system was developed and tested using panels of positive and negative sera, including samples obtained before the COVID-19 pandemic. The obtained sensitivity (90.48%) and specificity (93.65%) indicators with a ROC curve AUC = 0.9623 (OD450 = 0.213) indicate the diagnostic accuracy of the test system. The positive diagnostic ratio (LR+) = 14.25.0 indicates the reliability of a positive result. The domestically developed ELISA test system can be used for serological monitoring and assessment of the immune status of the population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute for Biological Safety Problems LLP, National Holding QazBioPharm JSC, Almaty 080409, Kazakhstan.
- Institute of Biotechnology, National Academy of Sciences of the Kyrgyz Republic, Bishkek 720071, Kyrgyzstan.
ORCID-Profile: Gulnur Nakhanova, Olga Chervyakova, Aisha Issabek, Sabina Moldagulova, Aziz Nakhanov
Förderung
- Science Committee of the Ministry of Education and Science
- scientific and technological programme “Development of new diagnostic test systems for particularly dangerous viral infections”
Zitieren
APA
Nakhanova, G., Chervyakova, O., Shorayeva, K., Issabek, A., Moldagulova, S., Zhunushov, A., Ulankyzy, A., Zhakypbek, A., Omurtay, A., Nakhanov, A., Absatova, Z., Shayakhmetov, Y., Jekebekov, K., Baiseit, T., & Kerimbayev, A. (2025). Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies. Methods and Protocols, 9(1), 4. https://doi.org/10.3390/mps9010004
Vancouver
Nakhanova G, Chervyakova O, Shorayeva K, Issabek A, Moldagulova S, Zhunushov A, et al. Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies. Methods and Protocols. 2025;9(1):4. doi:10.3390/mps9010004
BibTeX
@article{Nakhanova2025,
author = {Nakhanova, Gulnur and Chervyakova, Olga and Shorayeva, Kamshat and Issabek, Aisha and Moldagulova, Sabina and Zhunushov, Asankadyr and Ulankyzy, Aknur and Zhakypbek, Aigerim and Omurtay, Alisher and Nakhanov, Aziz and Absatova, Zharkinay and Shayakhmetov, Yeraly and Jekebekov, Kuanysh and Baiseit, Temirlan and Kerimbayev, Aslan},
title = {Development of an ELISA Using Recombinant Chimeric SM Protein for Serological Detection of SARS-CoV-2 Antibodies},
journal = {Methods and Protocols},
year = {2025},
volume = {9},
number = {1},
pages = {4},
doi = {10.3390/mps9010004}
}
EUVIMED